Nuvation Bio (NUVB) Competitors $2.08 +0.03 (+1.22%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. CPRX, HCM, IMVT, OGN, MIRM, AMRX, IBRX, XENE, BHC, and GMTXShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Immunovant (IMVT), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors Catalyst Pharmaceuticals HUTCHMED Immunovant Organon & Co. Mirum Pharmaceuticals Amneal Pharmaceuticals ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Nuvation Bio (NYSE:NUVB) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability. Is NUVB or CPRX more profitable? Catalyst Pharmaceuticals has a net margin of 36.91% compared to Nuvation Bio's net margin of -5,534.21%. Catalyst Pharmaceuticals' return on equity of 42.45% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% Catalyst Pharmaceuticals 36.91%42.45%36.59% Which has more volatility & risk, NUVB or CPRX? Nuvation Bio has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Does the media refer more to NUVB or CPRX? In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Nuvation Bio. Catalyst Pharmaceuticals' average media sentiment score of 0.80 beat Nuvation Bio's score of 0.65 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in NUVB or CPRX? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, NUVB or CPRX? Catalyst Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M89.71-$567.94M-$2.35-0.88Catalyst Pharmaceuticals$491.73M5.34$163.89M$1.5713.72 Do analysts rate NUVB or CPRX? Nuvation Bio presently has a consensus target price of $7.17, indicating a potential upside of 245.38%. Catalyst Pharmaceuticals has a consensus target price of $32.83, indicating a potential upside of 52.43%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Catalyst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Catalyst Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryCatalyst Pharmaceuticals beats Nuvation Bio on 13 of the 17 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$706.04M$2.90B$5.50B$20.64BDividend YieldN/A2.64%5.39%3.77%P/E Ratio-0.8821.5027.4228.03Price / Sales89.71282.64398.5038.91Price / CashN/A41.4736.1321.91Price / Book1.517.518.014.60Net Income-$567.94M-$55.05M$3.16B$984.95M7 Day Performance6.14%3.05%2.08%2.95%1 Month Performance-15.48%5.80%4.38%5.53%1 Year Performance-29.06%6.15%35.81%14.66% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio3.4997 of 5 stars$2.08+1.2%$7.17+245.4%-31.0%$706.04M$7.87M-0.8860CPRXCatalyst Pharmaceuticals4.9309 of 5 stars$22.12-1.6%$32.83+48.4%+35.8%$2.70B$491.73M14.0980Positive NewsHCMHUTCHMED1.6084 of 5 stars$15.21+2.5%$19.00+24.9%-8.9%$2.65B$630.20M0.001,811Positive NewsIMVTImmunovant2.2361 of 5 stars$15.47-2.1%$38.33+147.8%-36.6%$2.64BN/A-5.65120OGNOrganon & Co.4.8276 of 5 stars$9.82+0.7%$18.00+83.3%-49.5%$2.55B$6.40B3.414,000Trending NewsMIRMMirum Pharmaceuticals3.4791 of 5 stars$50.28-0.1%$65.50+30.3%+45.8%$2.49B$336.89M-31.23140AMRXAmneal Pharmaceuticals3.3517 of 5 stars$7.91+1.2%$11.60+46.6%+28.0%$2.48B$2.79B-197.708,100IBRXImmunityBio2.074 of 5 stars$2.76-3.8%$12.25+343.8%-57.3%$2.44B$14.74M-4.76590Gap UpXENEXenon Pharmaceuticals3.3237 of 5 stars$31.49-1.7%$54.82+74.1%-8.7%$2.42B$9.43M-9.75210BHCBausch Health Cos3.2721 of 5 stars$6.11-1.1%$7.42+21.4%+0.0%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading Volume Related Companies and Tools Related Companies Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Immunovant Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives ImmunityBio Alternatives Xenon Pharmaceuticals Alternatives Bausch Health Cos Alternatives Gemini Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NUVB Stock Alerts